Press releases

March 23, 2017 Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults
Research outlining medically actionable approach, patient experiences in pilot program presented at American College of Medical Genetics Annual Clinical Genetics Meeting Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has expanded the menu of tests offered as part of its ongoing proactive genetic testing pilot program. The announcement was made during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix , where Invitae researchers also presented findings from the company's growing body of experience on the use of proactive testing. "Interest in using genetic information to make better health decisions is growing among patients and physicians alike. Proactive genetic testing for healthy adults can be done responsibly if it is based on proven research and focuses on actionable, useful results delivered in a clinical context, with physician guidance throughout the process," said Robert
Read more
March 22, 2017 Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA) , a neuromuscular disease that is one of the leading lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting , features a novel, custom methodology that offers significant improvements over current testing approaches. SMA is an autosomal recessive disorder and the second leading genetic disease in infancy behind cystic fibrosis affects. SMA affects approximately one in every 10,000 infants, while one in 50 people is a carrier for the disorder. The majority of SMA cases are caused by loss of the gene SMN1 , with variation in the number of copies of related gene, SMN2 , playing a role in mitigating the severity of the
Read more
March 14, 2017 Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it will be presenting seventeen posters and presentations at the 2017 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix . "Scientific understanding of genetic medicine continues to expand rapidly, making sessions such as the ACMG meeting essential for the genetics community," said Robert Nussbaum , MD, chief medical officer of Invitae . "The research we will be presenting at ACMG this year has implications for how genetic variants are identified and classified, as well as for physicians' use of genetic information to treat patients with a wide variety of conditions. By continually advancing science, we at Invitae believe we can help more people benefit from the use of genetic information to make informed health decisions." Invitae's presence at the meeting includes two platform presentations, one on the prevalence of copy number and
Read more
February 21, 2017 Invitae to present at the Cowen and Company 37th Annual Health Care Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company's management team will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at approximately 4:00 p.m. Eastern / 1:00 p.m. Pacific in Boston, Massachusetts . The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests
Read more
February 17, 2017 New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment
- Findings presented at the 2017 Genitourinary Cancers Symposium - New research suggests that a substantial fraction of patients with prostate cancer and a positive family history are at high risk of an inherited genetic mutation that might help inform their treatment options. Among those men with prostate cancer meeting NCCN guidelines for testing, these initial data support the concept that particulars in the family history cannot be used to predict pathogenic variants. The research was presented at the 2017 Genitourinary Cancer Symposium, February 16-18 , in Orlando, Florida . Patients in the study, which was conducted by the Tulane Cancer Center in New Orleans , were tested using a commercially available panel of 25-79 cancer-related genes from Invitae (NYSE: NVTA), one of the fastest growing genetic information companies. The study, Inherited pathologic mutations and family history in patients with prostate cancer (Abstract #185), was designed to find, evaluate, and characterize
Read more
February 13, 2017 Invitae reports revenue of $9.2 million in fourth quarter 2016 and projects strong volume and revenue growth in 2017
SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2016 and set guidance for 2017. Following are the company's financial results in 2016: Generated revenue of $9.2 million in the fourth quarter of 2016 and a total of $25.0 million for the year Reduced cost of goods sold (COGS) per sample accessioned from approximately $700 in the fourth quarter of 2015 to approximately $400 in the fourth quarter of 2016. This represents a 43% decrease in COGS per sample accessioned compared to the fourth quarter of 2015 Delivered approximately 57,000 billable reports for the full year 2016, roughly tripling the approximately 19,000 billable reports delivered in 2015. Additionally, the company reported that it accessioned approximately 59,000 samples in 2016, a nearly 200% increase compared to 2015 Delivered
Read more
January 30, 2017 Invitae to announce fourth quarter and year-end 2016 financial results and 2017 guidance and will host conference call on February 13, 2017
- Management to present at Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017 - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2016 financial results and provide 2017 guidance on Monday, February 13, 2017 , and Invitae's management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. During the call, Invitae's management team will briefly review financial results, guidance, and recent developments and will spend the majority of the call fielding questions from analysts and investors. Management also invites investors to submit questions to ir@invitae.com at any time leading up to or during the call. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 60742797. Additionally, Invitae announced that it
Read more
January 9, 2017 Invitae announces new leadership structure to drive global growth
- Sean George appointed as chief executive officer, Randy Scott to become executive chairman - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company. Current chairman and chief executive officer Randy Scott will become executive chairman of the board of directors and remain full time at the company. The appointments are effective immediately. "Sean and I share a common vision for how to bring genetic testing into mainstream medical practice and a passion for transforming healthcare for people around the world. Sean has been a relentless force behind our progress toward that goal, and we're looking forward to working together in our new roles as Invitae accelerates the growth of genetic testing world-wide," said Randy Scott , executive chairman of Invitae . "Personally, I'm excited to
Read more
January 6, 2017 Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company
- Grew volume 200% by delivering approximately 57,000 billable reports for the full year 2016 and approximately 20,000 billable reports in Q4, generating positive gross margins - - Added multiple new regional payers, securing coverage for more than 175 million covered lives - - Announced new biopharma partnership and acquired patient-centered data company AltaVoice to expand the Invitae Genome Network to include both genetic information and patient-centered data - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements with the nation's largest payers to provide coverage for more than 175 million lives in aggregate. For the year, Invitae met its volume guidance of 50,000-70,000 billable tests, delivering approximately 57,000
Read more
January 6, 2017 Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases
- Acquisition will enable more comprehensive understanding of inherited diseases through permission-based sharing of genetic information and patient insights - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has acquired AltaVoice (formerly PatientCrossroads), a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other unique partnerships, expands Invitae's Genome Network, designed to connect patients, clinicians, advocacy organizations, researchers, and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. AltaVoice amplifies the voice of patients to optimize the search for better treatments through multiple patient-centered programs, including "Patient Insights Networks℠" (PINs), which enable organizations to more
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 10.53 -0.02 -0.19% Volume: 245,188 20 minute delay March 28, 2017

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com